https://www.selleckchem.com/pe....ptide/tirzepatide-ly
It is anticipated that 210 participants will be enrolled during the first 3 years of this 4-year study. Accounting for attrition, an anticipated final sample size of 158 participants with an average of 3 annual study visits will be available at the completion of the study. Power analyses indicate that this sample size will provide 90% power to detect an average cognitive change of at least 0.23 standard deviations in either direction. StrokeCog will provide novel insight into the relationships between immune events and cogn
Curtir
Comentario
Compartilhar
